ASCO Study Abstract Shows Cizzle Bio’s CIZ1B Biomarker Test for Lung CancerCould Save $518M in Annual Medicare Costs
New study abstract published for ASCO: Cizzle Bio’s CIZ1B biomarker test for lung cancer could save Medicare up to $518M annually while expanding access to early detection.
With 95% sensitivity for Stage I and 96% NPV, CIZ1B could reduce unnecessary procedures and increase early-stage lung cancer detection, especially in high-risk Medicare populations.
Co-authored by healthcare economist Jennifer Hinkel, M.Sc., this study highlights the clinical and economic case for integrating CIZ1B into lung cancer screening protocols.
